Immunotherapy may provide a future where curing metastatic cancer is not a goal but a reality. Significant progress has already been made with the clinical success of check-point inhibitors and more recently, CAR-T cells. It is likely that combination immune-therapies will be required for optimal success against cancer. It is also likely that conventional cell based approaches that focus on T cells may not provide expected dividends, and that harnessing the innate immune response might bring greater rewards. In this regard, Natural Killer (NK) cells, occasionally considered the innate counterpart of T cells, offer huge potential. This review considers how and why this may be so and discusses the current state of play with respect to NK cell therapies for cancer. Importantly, it will detail our current knowledge of NK cell metabolism and demonstrate how this information can synergise with the rapidly evolving field of immunometabolism, to provide new, exciting and effective ways to treat a range of cancer types.
INTRODUCTION
The use of immunotherapy to treat a wide range of diseases has had global impact and in 2018, eight of the top ten selling drugs globally were antibodies (creative-biolabs.com). Indeed, immunotherapy has heralded a new era for cancer treatments as evidenced by the recent Nobel prize awarded to two Immunologists for their work on basic T cell regulation, which was subsequently translated into the first checkpoint inhibitors in clinical use [1] . Another significant breakthrough for cancer immunotherapy is the advent of CAR-T adoptive cell therapies [2] .
Most research efforts in this area to date have focused on T cells, reflecting the relative popularity of T cells in mainstream Immunology.
These therapies have not been without their problems and cytokine release syndrome (CRS) has been commonly observed in T cell therapies, with occasional fatal results [3] . CRS is largely due to intrinsic features associated with T cell biology and significant patient management is 2 of 17 required. As a result, the tide is turning and there is increasing recognition that there are probably better possibilities and increased potential for innate immune cells, in particular Natural Killer (NK) cells, to have impact in this arena [4] .
The potential of NK cells for immunotherapy has long been recognized. Over 40 years of accumulated evidence supports their key role in killing cancer cells in vivo where they are thought to be particularly important in the control of metastatic spread [5, 6] . This has been extensively reviewed elsewhere (including [7] ). Earliest efforts to harness NK cells focused on their activation in vivo using cytokines such as IL2 and although some anti-cancer efficacy was observed [8] , toxicity associated with high dose of cytokine administration e.g., vascular leaking syndrome, precluded further development [9] . Today, however, antibodies (e.g., Herceptin) for the treatment of Her2+ breast cancer, anti-CD20 treatments (e.g., Rituximab) for lymphoma and anti-GD2 treatment for neuroblastoma [10] . While these therapies have had a significant impact, it is well known that NK cell effector functions deteriorate as cancer progresses [11] and thus, NK cell contributions to such immunotherapies are less optimal than they could be [12] . It was recently demonstrated that impaired metabolism was linked to the progressive NK dysfunction (though abnormal expression of fructose-1,6-bisphosphatase enzyme) [11] . Understanding this immune dysfunction will help identify ways to improve current therapies.
NK cells are also used as a form of adoptive cell therapy and it is here that there is perhaps most potential for future therapies. A key benefit of adoptive cell therapy is that it allows manipulation of cells ex vivo using a variety of approaches and which can empower NK cells to survive and persist in vivo with enhanced effector functions. Adoptive NK cell therapies can use either autologous patient cells or a range of allogeneic NK (allo-NK) options [13] . The allo-NK cell options include healthy donor NK cells (with various matching options for KIR/HLA [14] ), CAR-NK cells (e.g., cord blood [15] or iPSC derived [16] ), NK cell lines (e.g., NK92), or indeed a combination of these (e.g., NK92-CAR-NK cells) [17] However, understanding how the common mechanisms in which the immunosuppressive environment of cancer specifically impacts on NK cells will help to design strategies to equip both autologous and allogeneic adoptively transferred NK cells to survive and persist in a patient for maximum beneficial effect.
Most strategies to modulate human NK cells ex vivo have focused on cytokine stimulations although specific NK cell check-point inhibitors are also under development [4] . However, it is the area of immunometabolism, the focus of this review, that is likely to have most significant impact over the next few years.
WHAT DO WE KNOW ABOUT NK CELL METABOLISM?
Glucose is a key fuel used by NK cells [18] and is taken up through cellular receptors including Glut1. Once inside the cell, there are two key pathways by which glucose can be metabolized (see Figure 1 ). Glycolysis is a series of enzymatic steps which breaks down glucose into two molecules of pyruvate. Pyruvate can either be metabolized to lactate and secreted from the cell, or it can enter the mitochondria to be metabolized further by oxidative phosphorylation (Oxphos). Oxphos is the process by which electrons are transferred along the electron transport chain (ETC) machinery, and which culminates to drive ATP synthase and generate ATP. In general, generation of ATP through Oxphos is more efficient compared to glycolysis with respect to molecules of ATP generated per molecule of glucose. Both glycolysis and Oxphos are generally measured using extracellular metabolic flux analysers. These essentially measure pH changes and oxygen consumption which, in combination with specific metabolic inhibitors, are used to measure glycolytic flux and Oxphos of purified cell populations. Quiescent, mature NK cells predominantly metabolise glucose by Oxphos [19] . However, when NK cells are activated by cytokine, they upregulate both glycolysis and Oxphos pathways [19] [20] [21] [22] . This makes sense from a cellular perspective as during homeostasis, the primary requirement is to maintain existing cellular processes; thus Oxphos is very efficient in this regard. However, when the immune system is activated, it needs to increase both the number of immune cells present and to arm them with effector molecules required to carry out their specific effector functions. Thus, while increasing energy production by upregulating Oxphos is an obvious thing to do, upregulating glycolysis flux is also beneficial as, in addition to generating ATP, it also generates many biosynthetic precursors that are required to provide the biochemical building blocks for protein synthesis and proliferation. neutral amino acids), SLC1A5 (glutamine uptake) and CD36 (for free fatty acid uptake). Glucose is metabolized by glycolysis to yield pyruvate which is either further metabolized to lactate (and secreted) in the cytotosol, or converted to acetyl-Co-A for uptake into the mitochondria. It is initially converted to citrate as part of the normal TCA cycle. However, most of the citrate is then exported out of the mitochondria. It is processed by the ATP citrate lyase enzyme to generate acetyl-CoA (and oxaloacetate, OAA). Acetyl-Co-A in the cytosol is used for both lipid synthesis and acetylation reactions. The OAA generated is metabolized to malate which reenters the mitochondria, completing the cycle. This shuttle is known as the Citrate Malate Shuttle (CMS). The CMS can provide reducing equivalents that are required by the electron transport chain for the process of Oxidative Phosphoyrlation (Oxphos).
In line with this, uptake of nutrients from the environment is important for immune cells that are transitioning into effector cells [23] . This is also an obvious place where pathological changes, e.g., glucose deprivation in a tumour, or increased lipid availability during obesity, cells. This field is in its infancy and these receptors represent the simplest first round of analysis that has been easily achieved by routine flow cytometry methods. As our knowledge expands, so too will investigations into the large range of molecules and receptors that are inevitably involved in regulating complex immune changes e.g., SLC7a5 (also known as LAT) [24] , ferroportin (iron export receptor) [25] or CD36 (free fatty acid uptake).
Specialised NK Cell Subsets Differ in Their Metabolic Profiles
Many NK cell subsets have been defined based on phenotypic and functional differences [26] . A number of studies have demonstrated that CD56 bright cells are more metabolically responsive, whether they are from peripheral blood or tissue resident [22, 27] . While CD98 is expressed on all NK cells (and is upregulated in response to cytokine), CD71 is generally only present at low levels and increases preferentially on CD56 bright cells upon activation.
The glutamine receptor (SLC1A5) is also preferentially upregulated on peripheral blood CD56 bright NK cells in response to cytokine [28] .
There are also two studies within the last year that have defined on Oxphos, at least in terms of facilitating cytotoxicity [29] . It should be noted that most experiments were done on expanded NK cells and differences were not statistically significant when using primary cells.
However, the suggestion that increased glycolysis is important for licensed cells is also supported by Pfeiffer et al., for KIR+ licensed NK cells [30] . That metabolic differences were also observed between KIR+ and NKG2A+ educated NK cells in this latter study suggests that metabolic differences resulting from alternative signaling pathways to evoke licensing may be possible. [25] . In addition to phenotypic and functional differences, metabolic differences were also identified between trNK and cNK cells within the uterus. In addition to increased expression of receptors important for lactate and iron export, trNK cells also had higher expression of genes relating to cholesterol storage and homeostasis, compared to cNK. The authors speculated that CXCR6+ ILC1 cells in the uterus provided "innate" memory as they preferentially expanded in second pregnancies. As previous work on memory CD8 cells has defined a "futile fatty acid synthesis" pathway [32] , this may be a good place to start. Irrespectively, these data provide strong evidence for specific metabolic signatures that can now be investigated at a cellular and biochemical level.
NK Cells Adopt a Novel Metabolic Configuration
While glucose is the key fuel for glycolysis, we know that Oxphos can be fuelled in a number of different ways. [34] . The potential of these for regulating NK cell biology is under investigation.
MECHANISMS REGULATING NK CELL METABOLISM
Cytokines that activate NK cells clearly also drive metabolic reprogramming with increases in both glycolysis and Oxphos in NK cells reported. Some of the key regulators driving metabolic change include the transcriptions factors mTORC1, c-Myc and Srebp, and the transcriptional regulator ARID5B (reviewed elsewhere [35] ). However, this field is only in its infancy and much basic biology awaits discovery. It is likely that NK cell metabolism is regulated at many levels including transcriptional, translational, post-translation and epigenetic levels. It will be through a detailed understanding of the mechanisms underpinning NK cell metabolism and function that we will best be able to arm NK cells for immunotherapy. Indeed, although IL15 is a strong driver of NK cell metabolic reprogramming, sustained and prolonged signaling during expansion of human cells for adoptive immunotherapy can actually result in an exhausted NK cell phenotype [36] . Care must be also taken in extrapolating experimental data from T cells as different receptors, including possible check-point inhibitors, cytokine responsiveness and metabolism distinguish these cell types.
Ourselves and others have reported that TGFβ can inhibit NK cell metabolism [37, 38] . However, in the last year, two new mechanisms of negative regulation have been identified (see Figure 2) . mTORC1 is the most consistently defined positive regulator of NK cell metabolism to date. mTOR is a highly conserved serine/threonine kinase. It, along with activity; however, mTORC2 suppressed mTORC1 activity by reducing p-STAT5 and SLC7A5 expression [41] . Thus, while mTORC1 activity promotes NK cell metabolism, mTORC2 activity appears to inhibit it. An unanticipated role for the transcription factor Rfx7 was discovered when expression profiles and knock-out phenotype revealed high levels in NK cells and a heightened metabolic response when Rfx7 was absent [42] . The data suggested that Rfx7 is a negative regulator of important metabolic activities including glycolysis, Oxphos and nutrient receptor expression (CD98). mTORC1 activity was increased in the absence of Rfx7 and limiting mTORC1 activity (using genetic tools) suggested that Rfx7 Thus a common theme emerges where nutrient receptor expression is a key mechanism regulating NK cell metabolism, whether during homeostasis or activation [24, 41, 42] . Expression of receptors, in particular, SLC7a5, is increased through CD122 (IL15 or IL2) mediated signaling, and c-Myc is important in this process [24] . This axis can then be negatively regulated by Rfx7 (during homeostasis) and/or mTORC2 (during activation) and/or by modulation of both mTORC1 and p-STAT-5 signalling pathways [41, 42] .
POTENTIAL MECHANISMS TO "INTRINSICALLY" IMPROVE NK CELLS FOR ADOPTIVE IMMUNOTHERAPY
Adoptive cell therapy has a key advantage over in vivo manipulation of cells in terms of being able to genetically, pharmacologically or biologically manipulate NK cells to improve their effectiveness in vivo.
The potential to engineer a perfect anti-cancer effector cell is there but a suite of solutions will probably be required, tailoring NK cells depending on the source of NK cell, cancer type, staging, time of intervention etc. A non-exhaustive list of potential interventions is shown in Figure 3 and where these relate to metabolism, they will be discussed briefly below. Promote in vivo longevity: Allogeneic adoptively transferred cells will ultimately be removed by the host immune response and the kinetics of this can limit their effectiveness. Indeed, the success of NK cell adoptive cell therapy is improved by longevity and persistence of effector cells [43] . As a result, various strategies continue to be investigated including engineering IL15 into CAR-NK cells constructs, an approach which significantly increased survival of CAR-NK cells in a Raji xenograft model [44] .
As metabolism is fundamentally linked with survival, it has the potential to provide many targets by which to increase NK cell longevity Identification of CIS (encoded by Cish) as a strong negative regulator of IL15 signalling revealed it as a potential target to promote enhanced metabolism, longevity and function of NK cells in vivo [51] . Indeed, Cish(−/−) mice had enhanced IL15 signalling and resistance to metastases in prostate, melanoma and breast cancer models [51] .
Protect from the tumour microenvironment: Adoptive cell therapies involve sending cells into hostile environments created by cancer. Nutrients may be in short supply. Tumours are often hypoxic and numerous mechanisms by which tumours suppress NK cells are already identified [52] . Cells could be engineered to improve survival in this environment, e.g., TGFβ is often found elevated in cancer and is a known suppressor of NK cell metabolism and function [37, 38] . Similarly, PGE2
produced by tumour cells can inhibit NK cells [53] . Improved tumour access and/or modulation: While the main focus of this review has been on intrinsic mechanisms of NK cell regulation, it would be foolish to disregard the importance of NK cell extrinsic mechanisms in improving NK cell therapies. Indeed, it is likely that the combined synergy will ultimately provide the greatest benefit for patients. Manipulation of the tumour microenvironment, e.g., antibody
blockade of tumour derived adenosine, may improve NK cell activity [55] . Indeed, a recent report demonstrated a benefit from combined targeting of adenosine production by tumour cells with an NKG2D
expressing CAR-NK cell in various tumour models [56] . Furthermore, while it is generally acknowledged that tumour infiltrating lymphocytes are a good prognostic indicator in cancer, NK cells are more likely to be found on the periphery of tumours [57, 58] . Improved recruitment to tumour e.g., by MIP1α Finally, improved longevity of NK cells could also support NK cells in their role of preventing metastatic spread of tumours, in part by modulatation of tumour architecture as recently described by Glasner et al. [61] .
CONCLUDING REMARKS
The introduction of immunotherapy has changed the landscape of medical oncology. The on-going success of a range of immunotherapeutic interventions means that they are here to stay, and are likely to become increasingly used into the future. As a result, it is imperative that there is increased collaboration and communication between cancer and immunology fields. Because cancer cells have an altered metabolism, this has become a potential target for their preferential killing compared to healthy cells (reviewed in [62] ). However, many of these drugs also have the potential to interfere with immune cell metabolism [63] . One example is rapamycin which, alone or in combination, is in numerous clinical trials (over 1000 registered at www.clinicaltrial.gov). Some of these include treatments that involve NK cell mediated killing of antibody coated tumours cells, e.g., anti-GD2 for neuroblastoma, anti- where JAK inhibitors (JAKi) were evaluated to target breast cancer as the JAK-STAT pathway is commonly activated in these cells. However, the drugs actually increased the metastatic burden in pre-clinical models due to inhibition of NK cell control of metastatic spread [64] .
Moving to a focus on adoptive cell therapy also has the potential to circumvent the need to restore dysregulated autologous NK cell functions in patients which remains a much bigger challenge. For example, there may be scope to use engineered off-the-shelf NK cell as effectors for antibody based targeted therapies, e.g., anti-CD20 for lymphoma, or to use allo-NK cells during remission as a prophylactic strategy against metastatic disease.
In conclusion, numerous new therapies harness, manipulate and target the immune system to fight against cancer in a myriad of different ways. The success of these treatments will likely lead to their increased use, and to their becoming standard-of-care for a variety of cancers.
However, we are just at the beginning of this road and the potential for continued improved therapies is likely to pave the way to cure diseases, e.g., metastatic cancers, that are currently beyond our capabilities.
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